Core Viewpoint - The article discusses the recent trading activity of iFlytek Medical Technology (02506.HK), highlighting the fluctuations in southbound capital holdings and the company's focus on AI-enabled healthcare solutions [1] Group 1: Southbound Capital Activity - On February 13, southbound capital increased its holdings in iFlytek Medical Technology by 19,500 shares [1] - Over the past five trading days, there were three days of net reductions, totaling 283,600 shares [1] - In the last 20 trading days, there were ten days of net increases, amounting to 40,700 shares [1] - Currently, southbound capital holds 5,154,200 shares of iFlytek Medical Technology, representing 6.66% of the company's issued ordinary shares [1] Group 2: Company Overview - iFlytek Medical Technology Co., Ltd. primarily provides AI-enabled healthcare solutions in China [1] - The company's business lines include grassroots medical services (intelligent medical assistants and chronic disease management), hospital services (smart hospital solutions and diagnostic assistants), and patient services (smart hospital patient services and post-discharge management) [1] - The company also offers regional management platform solutions, including smart health solutions and smart medical insurance [1] - iFlytek Medical Technology mainly operates in the domestic market [1]

Core Viewpoint - Yahua Electronics (301337) is experiencing a concentration of shareholders, with a forecast for 2025 indicating a narrowing of losses, progress in brain-computer interface (BCI) business, and delays in some fundraising projects [1][2][3][4][5] Shareholder Concentration - As of January 31, 2026, the number of shareholders decreased to 12,161, a reduction of 668 shareholders or 5.21% compared to January 20, indicating a trend of concentration [2] Financial Performance - The company forecasts 2025 revenue between 250 million to 270 million yuan, with a net loss attributable to shareholders expected to be between 12 million to 17 million yuan, representing a reduction in losses by 35.82% to 54.69% year-on-year [3] Business Development - Progress has been made in the brain-computer interface business, with the initial integration of BCI and smart ward systems completed, leading to the launch of a brain-smart ward solution [4] Project Updates - The company announced delays in the "Research and Development Center Construction Project" and "Marketing Network Construction Project," with the expected usable status date pushed to December 31, 2027, to adapt to market changes and mitigate risks [5]

Core Viewpoint - Southbound funds increased their holdings in iFlytek Medical Technology (02506.HK) by 13,400 shares on February 12, indicating a fluctuating interest from investors in the company [1] Group 1: Southbound Fund Activity - Over the past five trading days, there were three days of net reductions in holdings, totaling a decrease of 227,900 shares [1] - In the last twenty trading days, there were ten days of net increases, with a total increase of 326,000 shares [1] - As of now, southbound funds hold 5,134,800 shares of iFlytek Medical Technology, representing 6.63% of the company's total issued ordinary shares [1] Group 2: Company Overview - iFlytek Medical Technology Co., Ltd. primarily provides AI-enabled medical solutions in China [1] - The company's business lines include grassroots medical services (comprising intelligent medical assistants and chronic disease management), hospital services (including smart hospital solutions and diagnostic assistants), and patient services (such as smart hospital patient services and post-discharge management) [1] - The regional management platform solutions business line includes smart health solutions and smart medical insurance [1]

Company Initiatives - The company’s board approved the issuance of H-shares and plans for listing on the Hong Kong Stock Exchange, with a shareholder meeting scheduled for early 2026 to discuss this initiative, marking a key step in its internationalization strategy [2] - The company has changed its stock name from "福瑞股份" to "福瑞医科" to reflect its long-term focus on medical technology [5] Regulatory Situation - In December 2025, the company received a warning letter from the Inner Mongolia Securities Regulatory Bureau due to inadequate internal controls and irregular revenue accounting related to its overseas subsidiaries, and submitted a rectification report by the end of the month [3] Industry Policy and Environment - The revised Drug Administration Law Implementation Regulations will take effect on May 15, 2026, emphasizing innovation in drug development and clinical value, which is expected to benefit the demand for the company’s FibroScan series products [4] Financial Performance - For the first three quarters of 2025, the company reported revenue of 1.101 billion yuan, a year-on-year increase of 12.37%, and a net profit of 112 million yuan, up 9.69% from the previous year [6] - As of February 10, 2026, the company’s total market capitalization was approximately 18.347 billion yuan, with a stock price increase of 5.16% on that day, and it has attracted holdings from multiple public funds [6]

Core Viewpoint - Rongke Technology (300290) is focusing on "AI + healthcare" strategic layout and aims to improve performance by optimizing costs and receivables in 2026 [1] Group 1 - The company is committed to enhancing profitability through capital operations that align with its development strategy, with any plans to be disclosed in compliance with regulations [1] - As of February 11, 2026, the company’s Secretary reiterated that there are currently no significant matters to disclose, including asset restructuring or cross-industry merger plans [1]

认知处理速度训练之所以效果显著，可能与其自适应设计有关。训练难度会根据参与者每次的表现实时 调整，从而持续激发认知挑战。此外，这种训练主要依赖内隐学习，即通过反复练习无意识提升反应速 度与视觉信息处理能力，而非依赖记忆事实或学习明确策略。这与记忆和推理训练所涉及的外显学习机 制不同，可能对大脑神经连接的保护与强化作用更为持久。 该研究进一步证实，即使是一次相对简短、非药物性的认知干预，也可能对延缓痴呆症发病产生长达数 十年的积极影响。专家表示，若能通过此类训练将痴呆症发病时间推迟，将对公共健康体系及减少社会 经济负担产生深远意义。 （文章来源：科技日报） 根据发表在新一期《阿尔茨海默病与痴呆症：转化研究与临床干预》上的研究，一项为期5到6周的认知 处理速度训练，可以帮助65岁及以上老年人在未来长达20年中，显著降低罹患痴呆症的风险。这是首个 针对认知训练长期效果的大规模随机对照试验。 约翰斯·霍普金斯大学医学院团队于1998至1999年间招募了2802名健康老年人，将其随机分为四组：三 组分别接受记忆力、推理能力或认知处理速度训练，另一组作为对照。每位参与者接受了为期5到6周、 每次60至75分钟的训练课程。 ...

天眼查显示，近日，广东荷塘生华医疗科技有限公司成立，法定代表人为蒋云，注册资本1000万人民 币，由北京荷塘生华医疗科技有限公司全资持股。 企业名称广东荷塘生华医疗科技有限公司法定代表人蒋云注册资本1000万人民币国标行业科学研究和技 术服务业>研究和试验发展>工程和技术研究和试验发展地址深圳市龙岗区宝龙街道宝龙社区宝荷大道 76号智慧家园二期3A202企业类型有限责任公司(法人独资)营业期限2026-2-11至无固定期限 来源：市场资讯 经营范围含一般经营项目是：医学研究和试验发展；技术服务、技术开发、技术咨询、技术交流、技术 转让、技术推广；物业管理；企业管理咨询；非居住房地产租赁；货物进出口；技术进出口。（除依法 须经批准的项目外，凭营业执照依法自主开展经营活动），许可经营项目是：药品生产。（依法须经批 准的项目，经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件为准） 序号股东名称持股比例1北京荷塘生华医疗科技有限公司100% ...

时隔两年半后再次访华的盖茨，对中国和世界又有了新的认识。 时隔两年半后，盖茨基金会主席比尔·盖茨再次回到中国。 他还表示，基金会在北京联合创办了全球健康药物研发中心，也对上海创办的全球健康创新研究院提供 了赠款支持。作为微软的创始人，盖茨还透露他在10日下午还参观了微软亚洲研究院在上海的实验室。 盖茨表示，上述机构都在进行着卓越的研究工作。 盖茨此次行程首先抵达中国海南，参观、了解中国在农业领域的创新进展，随后抵达上海，关注于传染 病防控和母婴健康，上述三大领域都是盖茨基金会（以下简称"基金会"）关注的重点。2月11日傍晚， 盖茨还意外在上海张江现身，出席一场名为"行动创造希望"的活动。 在行程间隙，盖茨接受了第一财经记者的专访。在专访中，盖茨就对华合作、人工智能潜力乃至围绕其 个人声誉的争议，都进行了坦诚和系统的回应。这是盖茨在2023年6月到访北京后的首次访华。在过去 30年中，盖茨到访中国20多次。 始终看好中国创新 "中国在过去三代人的时间里，积累了大量的农业发展和教育改善的经验，其实可以问问你们的祖父 母，在（中国）取得这些成功前，是什么样子的"，在专访伊始，盖茨就以此称赞中国在短期内实现现 代化的 ...

Core Viewpoint - The article highlights the recognition of 305 projects in the 2024 Zhejiang Provincial Science and Technology Awards, emphasizing the importance of innovation and competitive business environment in the region [1]. Group 1: Award Categories - The awards include 298 projects in Natural Science, Technological Invention, and Scientific and Technological Progress, along with 7 projects in International Scientific and Technological Cooperation [1]. - The Natural Science Award, Technological Invention Award, and Scientific and Technological Progress Award are the main categories recognized in the event [3][8]. Group 2: Notable Achievements - Several projects were awarded for their contributions to various fields, including chronic airway diseases, micro-nano optical fiber structures, and metabolic mechanisms in sports system injuries [2][4]. - The awards reflect significant advancements in research and technology, showcasing the capabilities of institutions like Zhejiang University and other collaborating entities [2][5]. Group 3: Research Focus Areas - Key research areas recognized include the mechanisms of aging inflammation in chronic diseases, low-dimensional perovskite materials for efficient light-emitting devices, and the development of advanced algorithms for tumor analysis [2][6]. - The awards also cover innovative approaches in environmental protection, such as the degradation of new pollutants and the study of heavy metal transport mechanisms in soil [6][7].

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in iFlytek Medical Technology (02506.HK) by 186,500 shares on February 10, 2026, marking a decrease of 3.44% [1][2] - Over the past five trading days, there have been four days of reductions in holdings, totaling a net decrease of 210,700 shares [1] - In the last 20 trading days, there were 11 days of increased holdings, with a cumulative net increase of 1,308,000 shares [1] Group 2 - As of now, southbound funds hold 5,231,600 shares of iFlytek Medical Technology, which represents 6.76% of the company's total issued ordinary shares [1] - The company primarily engages in providing AI-powered medical solutions, with business lines including grassroots medical services, hospital services, patient services, and regional management platform solutions [2] - The grassroots medical services line consists of intelligent medical assistants and chronic disease management, while the hospital services line includes smart hospital solutions and diagnostic assistance [2]